Sleeve Gastrectomy

Bariatric Surgery Versus Emerging Medication Treatments

BY DR PATRICK NOEL

March 8, 2024

Introduction

Obesity, a global epidemic, has long been a formidable challenge within the realm of public health, contributing to a myriad of health issues such as type 2 diabetes, hypertension, and cardiovascular diseases[1]. In an era where the prevalence of obesity continues to rise alarmingly, the quest for effective treatment modalities has become more crucial than ever. Among the array of options available, bariatric surgery and emerging medication treatments stand out as two primary strategies in the battle against obesity. This article sets out to explore these two distinct approaches, providing a balanced comparison of their benefits, risks, and the evolving landscape of obesity treatment.

Bariatric surgery, with procedures like gastric bypass and sleeve gastrectomy, has been a beacon of hope for individuals with severe obesity, offering significant and sustained weight loss and an improvement in obesity-related comorbidities[2]. Despite its effectiveness, bariatric surgery is not without risks; complications can arise, and patients need to commit to lifelong dietary and lifestyle changes[3].

Parallel to surgical interventions, the development of pharmacological treatments has marked a significant advancement in obesity care. Recent years have seen the introduction of several promising medications that act on different pathways of the body to reduce appetite and increase satiety[4]. These medications offer a non-invasive alternative to surgery, potentially widening the reach of effective obesity treatments.

However, while both treatment modalities present viable options, they also raise questions regarding long-term efficacy, safety, and accessibility. The comparison between the two reveals not just their respective merits but also underscores the importance of a personalized approach to obesity treatment, taking into account the individual patient’s health profile, preferences, and the potential for integrating different treatment strategies[5].

As we delve into the intricacies of bariatric surgery versus emerging medication treatments, this article aims to shed light on the current state of obesity treatments, offering insights into their future direction and the ongoing efforts to provide effective, accessible, and sustainable solutions for those grappling with obesity.

Understanding Obesity

Obesity is not merely a cosmetic concern but a complex medical condition that significantly increases the risk of other diseases and health problems, such as heart disease, diabetes, high blood pressure, and certain cancers[6]. This section aims to delve into the definition, classification, and health risks associated with obesity, providing a foundational understanding necessary for evaluating the comparative effectiveness of bariatric surgery and medication treatments.

Definition and Classification

Obesity is defined as abnormal or excessive fat accumulation that presents a health risk. A crude measure of obesity is the Body Mass Index (BMI), which is calculated by dividing a person’s weight in kilograms by the square of their height in meters (kg/m²). Adults with a BMI of 30 or over are considered obese[7]. However, it’s important to acknowledge that BMI does not differentiate between excess fat, muscle, or bone mass, nor does it indicate the distribution of fat among individuals.

Health Risks Associated with Obesity

The health implications of obesity are vast and multifaceted. Obesity significantly increases the risk of developing chronic conditions such as type 2 diabetes, cardiovascular diseases, and certain forms of cancer. For instance, obesity is a major risk factor for type 2 diabetes, with nearly 90% of people living with type 2 diabetes being overweight or obese[8]. Moreover, obesity contributes to hypertension and cardiovascular diseases by increasing blood pressure and cholesterol levels, which can lead to stroke and heart attack[9]. Additionally, obesity is linked to an increased risk of certain cancers, including breast, colon, and kidney cancers[10].

Understanding the gravity of obesity and its health implications is crucial for both individuals and healthcare providers to make informed decisions about treatment options, including bariatric surgery and emerging medication treatments.

Bariatric Surgery: An Overview

What is Bariatric Surgery?

Bariatric surgery encompasses a variety of procedures designed to induce weight loss by altering the human digestive system[11]. The most common forms of these surgeries include gastric bypass, sleeve gastrectomy, and adjustable gastric banding, each carrying its own distinct method of operation. Gastric bypass involves rerouting the digestive system to bypass most of the stomach and part of the intestine, drastically reducing the amount of food one can eat and the calories absorbed[12]. Sleeve gastrectomy, on the other hand, involves removing a significant portion of the stomach, leaving a smaller, tube-shaped stomach.

Eligibility and Types

Eligibility for bariatric surgery typically requires patients to meet specific criteria, including a body mass index (BMI) of 40 or higher or a BMI of 35 or higher with obesity-related comorbidities, such as type 2 diabetes or hypertension[13]. These surgeries are considered when traditional methods of weight loss, such as diet and exercise, have failed to yield significant results.

Advantages of Bariatric Surgery

The benefits of bariatric surgery extend beyond substantial weight loss. Studies have shown that bariatric surgery can lead to the remission of type 2 diabetes, improvement in cardiovascular risk factors, and a reduction in mortality rates among patients with severe obesity[14]. Moreover, many patients experience improvements in quality of life, including mobility, self-esteem, and mental health.

Risks and Considerations

Despite its benefits, bariatric surgery is not without risks. Surgical complications, nutritional deficiencies, and the need for lifelong dietary changes are significant considerations[15]. Patients must undergo thorough evaluations and commit to long-term follow-up care to mitigate these risks.

Emerging Medication Treatments

Overview of Pharmacological Approaches

The landscape of obesity treatment is witnessing a paradigm shift with the advent of pharmacological interventions aimed at managing this complex condition. These approaches offer a promising alternative for individuals seeking non-surgical options for weight loss, addressing the need for comprehensive and accessible obesity treatments[6].

Key Medications

Among the forefront of these innovations is semaglutide, a medication that has garnered attention for its effectiveness in weight management by mimicking the GLP-1 hormone, which plays a crucial role in appetite regulation[16]. Initially developed for the treatment of type 2 diabetes, semaglutide has demonstrated significant potential in reducing body weight in clinical trials, marking a breakthrough in the pharmacological treatment of obesity[17]. Other notable medications include liraglutide and the combination of bupropion and naltrexone, offering diverse mechanisms to combat obesity[18].

Advantages and Limitations

Advantages

The introduction of these medications represents a significant advancement in obesity treatment, providing a less invasive option compared to bariatric surgery. These treatments offer the possibility of significant weight loss without the need for surgical intervention, thereby expanding the accessibility of effective obesity treatments[19].

Limitations

Despite the promise of these emerging medications, there are limitations, including variability in patient response, concerns about long-term safety, potential side effects, and the economic burden associated with their use. The cost of these medications and their coverage by insurance plans remain significant hurdles to their widespread adoption[20].

Emerging medication treatments for obesity are reshaping the therapeutic landscape, offering new hope for individuals struggling with weight management. As the medical community continues to explore and understand the full potential of these treatments, they hold the promise of integrating into a holistic approach to obesity care, providing a complement to traditional lifestyle interventions and surgical options.

Comparative Analysis

Efficacy of Treatments

When comparing bariatric surgery to emerging medication treatments, the efficacy in terms of sustained weight loss and improvement in obesity-related comorbidities becomes a critical factor. Bariatric surgery has been consistently shown to result in significant long-term weight loss, with many patients experiencing an improvement or complete resolution of conditions such as type 2 diabetes, hypertension, and obstructive sleep apnoea[3]. On the other hand, pharmacological treatments, while effective in inducing weight loss and managing comorbidities, generally produce less dramatic results compared to surgery[4]. However, the gap between the efficacy of these two approaches may narrow as newer, more effective medications are developed and approved.

Quality of Life and Patient Satisfaction

Another important aspect to consider is the impact of each treatment on the patient’s quality of life and overall satisfaction. Studies have indicated that bariatric surgery can significantly improve the quality of life for individuals with severe obesity[21]. Medication treatments, by being less invasive, also contribute to improved quality of life, particularly in terms of avoiding the risks and recovery time associated with surgery[21]. Patient satisfaction tends to be high with both treatments, although it is closely linked to the extent of weight loss achieved and the reduction in obesity-related health issues[22].

Cost-effectiveness

From a healthcare system perspective, the cost-effectiveness of obesity treatments is paramount. Bariatric surgery, despite its higher upfront costs, is cost-effective in the long term due to the reduction in obesity-related healthcare costs and the improvement in patients’ health status[23]. Medication treatments, while having lower initial costs, may require ongoing expenditure, and their long-term cost-effectiveness is still under investigation[24].

Both bariatric surgery and emerging medication treatments offer viable paths for obesity management, each with its own set of advantages and limitations. The choice between these options should be tailored to the individual patient’s health profile, preferences, and specific needs, with a multidisciplinary approach ensuring the best possible outcomes.

Conclusion

In conclusion, the choice between bariatric surgery and emerging medication treatments for obesity management depends on a multifaceted array of factors, including the individual’s health status, the severity of obesity, comorbid conditions, and personal preferences[25]. Bariatric surgery offers substantial and sustained weight loss with the potential to significantly improve, if not resolve, obesity-related comorbidities, thereby enhancing the overall quality of life[26]. However, it comes with its inherent risks and necessitates a lifelong commitment to dietary and lifestyle modifications[27].

Emerging medication treatments, on the other hand, provide a less invasive option with the convenience of avoiding surgical risks. These pharmacological interventions are continually evolving, showing promise in their efficacy and ability to improve patient outcomes[28]. Despite this, their long-term effects, safety profiles, and economic implications require further exploration[4].

Ultimately, the decision-making process should involve a thorough discussion between the patient and a multidisciplinary team of healthcare professionals, considering all available options and tailoring the approach to the individual’s needs and circumstances. As research advances and more treatment options become available, the landscape of obesity management will continue to evolve, offering hope and improved outcomes for those affected by obesity[29].

References

World Health Organization. (2020). Obesity and overweight. *World Health Organization*.
Adams, T. D., Davidson, L. E., Litwin, S. E., Kolotkin, R. L., LaMonte, M. J., Pendleton, R. C., … & Hunt, S. C. (2017). Health benefits of gastric bypass surgery after 6 years. *JAMA*, 308(11), 1122-1131.
Courcoulas, A. P., Christian, N. J., Belle, S. H., Berk, P. D., Flum, D. R., Garcia, L., … & Wolfe, B. M. (2014). Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. *JAMA*, 310(22), 2416-2425.
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016). Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. *JAMA*, 315(22), 2424-2434.
Bray, G. A., & Kim, K. K., Wilding, J. P. H. (2021). Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obesity Reviews*, 22(7), e13195.
World Health Organization. (2020). *Obesity and overweight factsheet*. World Health Organization.
National Institutes of Health. (2013). *Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults*.
American Diabetes Association. (2018). *Statistics About Diabetes*. American Diabetes Association.
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006). Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. *Arteriosclerosis, thrombosis, and vascular biology*, 26(5), 968-976.
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K.; International Agency for Research on Cancer Handbook Working Group. (2016). Body Fatness and Cancer — Viewpoint of the IARC Working Group. *New England Journal of Medicine*, 375, 794-798.
Buchwald, H., & Oien, D. M. (2013). Metabolic/bariatric surgery Worldwide 2011. *Obesity Surgery*, 23(4), 427-436.
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., … & Kashyap, S. R. (2017). Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. *New England Journal of Medicine*, 376(7), 641-651.
American Society for Metabolic and Bariatric Surgery. (2020). Who is a Candidate for Bariatric Surgery?. *ASMBS*.
Adams, T. D., Davidson, L. E., Litwin, S. E., Kolotkin, R. L., LaMonte, M. J., Pendleton, R. C., … & Hunt, S. C. (2012). Health benefits of gastric bypass surgery after 6 years. *JAMA*, 308(11), 1122-1131.
Mechanick, J. I., Youdim, A., Jones, D. B., Garvey, W. T., Hurley, D. L., McMahon, M., … & Kushner, R. (2013). Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. *Obesity*, 21(S1), S1-S27.
Pratley, R., Aroda, V., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., … & Garvey, W. T. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *The Lancet Diabetes & Endocrinology*, 6(4), 275-286.
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Semaglutide Obesity Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*, 384(11), 989-1002.
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., … & Dunayevich, E. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*, 376(9741), 595-605.
Ryan, D., Heaner, M. (2018). Emerging medications for treating obesity. *Endocrinology and Metabolism Clinics of North America*, 47(4), 943-956.
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., … & Still, C. D. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology & Metabolism*, 100(2), 342-362.
Sarwer, D. B., Wadden, T. A., Moore, R. H., Eisenberg, M. H., Raper, S. E., & Williams, N. N. (2010). Preoperative eating behavior, postoperative dietary adherence, and weight loss after gastric bypass surgery. *Surgery for Obesity and Related Diseases*, 6(5), 640-646.
Mitchell, J. E., King, W. C., Chen, J. Y., Devlin, M. J., Flum, D., Garcia, L., … & Pender, J. R. (2014). Course of depressive symptoms and treatment in the longitudinal assessment of bariatric surgery (LABS-2) study. *Obesity*, 22(8), 1799-1806.
Cremieux, P. Y., Buchwald, H., Shikora, S. A., Ghosh, A., Yang, H. E., & Buessing, M. (2008). A study on the economic impact of bariatric surgery. *American Journal of Managed Care*, 14(9), 589-596.
Neovius, M., Narbro, K., Keating, C., Peltonen, M., Sjöholm, K., Agren, G., … & Sjöström, L. (2012). Health care use during 20 years following bariatric surgery. *JAMA*, 308(11), 1132-1141.
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007). Long-term mortality after gastric bypass surgery. *New England Journal of Medicine*, 357(8), 753-761.
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., Bengtsson, C., Dahlgren, S., Gummesson, A., Jacobson, P., Karlsson, J., Lindroos, A. K., Lönroth, H., Näslund, I., Olbers, T., Stenlöf, K., … & Agren, G. (2007). Effects of bariatric surgery on mortality in Swedish obese subjects. *New England Journal of Medicine*, 357(8), 741-752.
Courcoulas, A., King, W. C., Belle, S. H., Berk, P. D., Flum, D. R., Garcia, L., Gourash, W., Horlick, M., Mitchell, J. E., Pories, W., Wolfe, B., & Yanovski, S. Z. (2014). Seven-year weight trajectories and health outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study. *JAMA Surgery*, 149(5), 427-434.
Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., Amiel, S. A., Kaplan, L. M., Taroncher-Oldenburg, G., & Cummings, D. E. (2016). Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. *Diabetes Care*, 39(6), 861-877.
Aminian, A., Brethauer, S. A., Kirwan, J. P., Kashyap, S. R., Burguera, B., & Schauer, P. R. (2015). How safe is metabolic/diabetes surgery? *Diabetes, Obesity and Metabolism*, 17(2), 198-201.